Trade Nektar Therapeutics - NKTR stock price

37.39
+0.02%
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
White Paper Declaration

NKTR price history

Date Close Change Chg% Open Min. Max.
2022-09-30 35.86 -1.96 -5.18 37.82 35.47 38.05
2022-09-30 38.32 0.89 2.38 37.43 37.09 38.94
2022-09-30 37.7 1.41 3.89 36.29 36.29 38.09
2022-09-30 36.88 -1.22 -3.20 38.1 36.54 38.73
2022-09-30 38.65 0.28 0.73 38.37 37.66 38.8
2022-09-30 38.95 1.54 4.12 37.41 37.41 39.59
2022-09-30 38.42 1.60 4.35 36.82 36.64 38.47
2022-09-30 37.72 0.84 2.28 36.88 36.65 38.13
2022-09-30 37.06 0.52 1.42 36.54 36.54 37.37
2022-09-30 36.95 -0.74 -1.96 37.69 36.36 37.69
2022-09-30 38.57 1.34 3.60 37.23 36.76 38.61
2022-09-30 37.92 -0.10 -0.26 38.02 37.92 40.01
2022-09-30 39.02 3.36 9.42 35.66 35.66 39.03
2022-09-30 36.42 1.13 3.20 35.29 35.14 36.56

Mobile app

Full trading account functionality: order execution and cancellation, stop-loss and take-profit setup, transaction history, deposits and withdrawals

iOS
4,7
12 127 reviews
Android
4,1
9 795 reviews
Dzengi Exchange
Trade BTC & tokenized stocks